Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series

Br J Haematol. 2021 May;193(4):e36-e38. doi: 10.1111/bjh.17413. Epub 2021 Mar 21.

Authors

Agnieszka Blum¹, Despina Bazou¹, Kay R Ting¹, Giada Bianchi², Monisa Mahandran³, Harshini Mahandran³, Stephen Eustace¹, Paul G Richardson², Peter O'Gorman^{1

3}

Affiliations

¹ Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.
² The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Haematology, Mater Private Hospital, Dublin, Ireland.

PMID: 33748981
DOI: 10.1111/bjh.17413

No abstract available

Keywords: immunomodulation; multiple myeloma; plasmacytoma; proteasome inhibitor; steroids.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Bone Neoplasms / diagnostic imaging
Bone Neoplasms / drug therapy*
Dexamethasone / administration & dosage
Diphosphonates / administration & dosage
Female
Humans
Magnetic Resonance Imaging
Male
Multiple Myeloma / diagnostic imaging
Multiple Myeloma / drug therapy*
Osteogenesis / drug effects*
Plasmacytoma / diagnostic imaging
Plasmacytoma / drug therapy*

Substances

Diphosphonates
Dexamethasone